Expectations of a hefty COVID-19 relief package under
President-elect Joe Biden and hopes of a rebound in corporate
earnings this year have eclipsed concerns over signs that the
labor market recovery has stalled amid rampant COVID-19
infections.
Wall Street's main indexes ended marginally higher on Tuesday on
a boost from economy-linked financials, energy and materials
stocks, while the small-cap Russell 2000, sensitive to domestic
outlook, closed at an all-time high.
Investors are watching events in Washington, where the U.S.
House of Representatives will vote on Wednesday to impeach
President Donald Trump over the storming of the U.S. Capitol
last week that stunned the nation and left five dead.
U.S. Federal Reserve officials on Tuesday said that concerns
about continued violence pose a risk, but the transition to a
new administration on Jan. 20 and a likely accelerating vaccine
rollout have left them optimistic.
The new Democratic-controlled Senate will take up further
COVID-19 relief legislation as soon as Democrats take control of
the chamber, U.S. Senate Democratic Leader Chuck Schumer assured
on Tuesday.
At 6:27 a.m. ET, Dow E-minis were down 12 points, or 0.04% and
S&P 500 E-minis were down 4 points, or 0.11%. Nasdaq 100 E-minis
were down 11.5 points, or 0.09%.
Earnings reports from big U.S. banks including JPMorgan and
Citigroup will mark the unofficial start to the fourth-quarter
earnings season later this week where investors will gauge
remarks from executives for clues on corporate America's health.
Exxon Mobil Corp added 0.9% after J.P. Morgan upgraded the stock
to "overweight", its first outright "buy" recommendation for the
oil major in seven years, saying cuts in capital spending had
put it on track for a stronger performance.
General Motors Co added another 3% in premarket trading on top
of Tuesday's 6% jump after the automaker announced its entry
into the growing electric delivery vehicle business.
Regeneron Pharmaceuticals climbed 3.5% in light trading as the
U.S. government said it would buy 1.25 million additional doses
of the company's COVID-19 antibody cocktail for about $2.63
billion.
(Reporting by Medha Singh in Bengaluru; Editing by Maju Samuel)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|
|